Evidence map›Paper›PMID 42573397›Full record

ArticleJournal of chemical information and modeling2026

From Dynamics to Diagnosis and Therapy: A Multiscale Computational Framework for MALT1-Targeted Cancer Theranostics.

Rodrigo M Santos, Teodorico C Ramalho

Abstract read
In one paragraph

Article in Journal of chemical information and modeling, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Rodrigo M SantosLaboratory of Molecular Modelling, Department of Chemistry, Federal University of Lavras, Lavras37200-000, Minas Gerais, Brazil.
Teodorico C RamalhoLaboratory of Molecular Modelling, Department of Chemistry, Federal University of Lavras, Lavras37200-000, Minas Gerais, Brazil.ORCID 0000-0002-7324-1353

Funding

Conselho Nacional de Desenvolvimento Cient?fico e Tecnol?gico 308248/2022-8Coordena??o de Aperfei?oamento de Pessoal de N?vel Superior NAFinanciadora de Estudos e Projetos NAFunda??o de Amparo ? i Pesquisa do Estado de Minas Gerais NAInstituto Nacional de Ci?ncia e Tecnologia em Defesa Qu?mica e Biol?gica 408584/2024-6Univerzita Hradec Kr?lov? VT2019-2021
6 · The paper itself

Abstract

Cancer is one of the leading causes of death worldwide, making it a major concern in modern society. Therefore, the proposal of strategies against this illness is of major importance and has been widely studied by the scientific community in the past decades. In this sense, these strategies mainly focus on achieving improved therapy and diagnosis, with some proposals focusing on developing chemical agents capable of both treating and diagnosing cancer through targeting a cancer-related biomarker. In the role of cancer-related targets, MALT1 shows great potential as a cancer biomarker, being related to the nuclear factor-κB (NF-κB) signaling activation, an important biochemical process that regulates immune responses and inflammatory events in the human body, and its malfunction is related to the development and survival of several types of cancer. Despite MALT1's importance as a cancer target, to the best of our knowledge, there is a lack of literature proposing chemical agents capable of treating and diagnosing cancer through this biomarker. Hence, the present work's main goal was to propose a theranostic agent for this task, for which a combination of biased MD simulations, convolutional variational autoencoders (CVAEs), and quantum calculations was used. From this, it was possible to propose and optimize a compound to achieve a good MALT1 allosteric inhibition ratio while also presenting different fluorescence in different environments, crucial for signaling purposes. From this, both compounds 1 and 2 showed a cyan enol emission to blue enol emission when compared between the water-only environment and the protein environment, a feature that may serve as a molecular signature of the signaling process induced by the compound. In addition, this result also sheds light on the major relevance of enol emission of ESIPT-based probes, a few explored characteristics in the literature, which mainly focus solely on keto emission. Now, regarding inhibition, compound 1 indicated that the use of a phenothiazine derivative was a good choice, and by making a simple modification in its phenothiazine portion to generate compound 2, the inhibition ratio more than doubled, from 29% for compound 1 to 71% for compound 2, with compound 2 being an optimized chemical agent that has promising action suitable for theranostics purposes. Hence, the presented results show a promising direction toward the development of cancer theranostics drugs targeting the MALT1 allosteric pocket and provide a powerful theoretical framework that can be extended to other biological systems.

Indexed as

Molecular Dynamics SimulationMucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 ProteinNeoplasmsTheranostic NanomedicineHumansMALT1 protein, humanMucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 Protein

Identifiers

PMID42573397
PMCPMC13471727

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.